Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects

Trial Profile

Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2018

At a glance

  • Drugs Ethinylestradiol/norgestimate (Primary) ; Evacetrapib (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jan 2013 New trial record
    • 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top